| Pharmaceutical Information |
| Drug Name |
Cisapride |
| Drug ID |
BADD_D02618 |
| Description |
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. |
| Indications and Usage |
For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
A03FA02 |
| DrugBank ID |
DB00604
|
| KEGG ID |
D00274; D02092
|
| MeSH ID |
D020117
|
| PubChem ID |
6917698
|
| TTD Drug ID |
D0BD8D
|
| NDC Product Code |
12578-431; 60592-031 |
| UNII |
UVL329170W
|
| Synonyms |
Cisapride | R-51619 | R 51619 | R51619 | Propulsid |
|
| Chemical Information |
| Molecular Formula |
C23H29ClFN3O4 |
| CAS Registry Number |
81098-60-4 |
| SMILES |
COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
